Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Death/intubation -125% Improvement Relative Risk HCQ for COVID-19  Saib et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? PSM prospective study of 104 patients in France Higher death/intubation with HCQ (not stat. sig., p=0.23) c19hcq.org Saib et al., PLOS ONE, June 2021 Favors HCQ Favors control

Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study

Saib et al., PLOS ONE, doi:10.1371/journal.pone.0252388
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
203 hospitalized patients in France, not showing significant differences with treatment. Confounding by indication is likely. Authors do not discuss confounding.
This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.
risk of death/intubation, 125.0% higher, RR 2.25, p = 0.23, treatment 9 of 52 (17.3%), control 4 of 52 (7.7%), PSM.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Saib et al., 9 Jun 2021, prospective, propensity score matching, France, peer-reviewed, 9 authors, average treatment delay 7.2 days.
This PaperHCQAll
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study
Anis Saib, Walid Amara, Pascal Wang, Simon Cattan, Azeddine Dellal, Kais Regaieg, Stephane Nahon, Olivier Nallet, Lee S Nguyen
PLOS ONE, doi:10.1371/journal.pone.0252388
Background Hydroxychloroquine combined with azithromycin (HCQ/AZI) has initially been used against coronavirus disease-2019 . In this retrospective study, we assessed the clinical effects of HCQ/AZI, with a 28-days follow-up. Methods In a registry-study which included patients hospitalized for COVID-19 between March 15 and April 2, 2020, we compared patients who received HCQ/AZI to those who did not, regarding a composite outcome of mortality and mechanical ventilation with a 28-days follow-up. QT was monitored for patients treated with HCQ/AZI. Were excluded patients in intensive care units, palliative care and ventilated within 24 hours of admission. Three analyses were performed to adjust for selection bias: propensity score matching, multivariable survival, and inverse probability score weighting (IPSW) analyses. Results Overall, 203 patients were included: 60 patients treated by HCQ/AZI and 143 control patients. During the 28-days follow-up, 32 (16.3%) patients presented the primary outcome and 23 (12.3%) patients died. Propensity-score matching identified 52 unique pairs of patients with similar characteristics. In the matched cohort (n = 104), HCQ/AZI was not associated with the primary composite outcome (log-rank p-value = 0.16). In the overall cohort (n = 203), survival and IPSW analyses also found no benefit from HCQ/AZI. In the HCQ/AZI group, 11 (18.3%) patients prolonged QT interval duration, requiring treatment cessation.
Supporting information S1 File. (XLSX) Author Contributions Conceptualization: Anis Saib, Lee S. Nguyen. Data curation: Anis Saib. Investigation: Walid Amara, Pascal Wang, Simon Cattan, Azeddine Dellal, Kais Regaieg, Stephane Nahon, Olivier Nallet, Lee S. Nguyen. Resources: Pascal Wang. Supervision: Lee S. Nguyen. Validation: Walid Amara, Simon Cattan, Azeddine Dellal, Kais Regaieg, Stephane Nahon, Olivier Nallet. Visualization: Lee S. Nguyen. Writing -original draft: Anis Saib. Writing -review & editing: Olivier Nallet, Lee S. Nguyen.
References
Aromolaran, Srivastava, Alı, Chahine, Lazaro et al., Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation, PLoS ONE, doi:10.1371/journal.pone.0208321
Austin, Stuart, The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes, Stat Methods Med Res, doi:10.1177/0962280215584401
Capel, Herring, Kalla, Yavari, Mirams et al., Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential, Heart Rhythm, doi:10.1016/j.hrthm.2015.05.027
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2019014
Choi, Lim, Chung, Choi, -G et al., Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice, BioMed Research International, doi:10.1155/2018/1574806
Consortium, Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results, New England Journal of Medicine, doi:10.1056/NEJMoa2023184
Cortegiani, Ippolito, Ingoglia, Iozzo, Giarratano et al., Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19, Journal of Critical Care, doi:10.1016/j.jcrc.2020.06.019
Costedoat-Chalumeau, Hulot, Amoura, Leroux, Lechat et al., Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases, Rheumatology, doi:10.1093/rheumatology/kel402
Danial, Hajage, Nguyen, Mastroianni, Demondion et al., Percutaneous versus surgical femoro-femoral veno-arterial ECMO: a propensity score matched study, Intensive care medicine, doi:10.1007/s00134-018-5442-z
De ´cret, prescrivant les mesures ge ´ne ´rales ne ´cessaires pour faire face à l'e ´pide ´mie de covid-19 dans le cadre de, l'e ´tat d'urgence sanitaire
Funck-Brentano, Nguyen, Salem, Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19, Lancet, doi:10.1016/S0140-6736%2820%2931528-2
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study, Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101663
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2012410
Group Rc, Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2022926
Guan, Ni, -Y, Hu, Liang et al., Clinical Characteristics of Coronavirus Disease 2019 in China, New England Journal of Medicine, doi:10.1056/NEJMoa2002032
Lunceford, Davidian, Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study, Statistics in Medicine, doi:10.1002/sim.1903
Mahevas, Tran, Roumier, Chabrol, Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv, doi:10.1101/2020.04.10.20060699
Nguyen, Dolladille, Drici, Fenioux, Alexandre et al., Cardiovascular Toxicities Associated with Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database, Circulation, doi:10.1161/CIRCULATIONAHA.120.048238
Nguyen, Suc, Kheav, Coutance, Carmagnat et al., Quadritherapy vs standard tritherapy immunosuppressant regimen after heart transplantation: A propensity score-matched cohort analysis. American journal of transplantation: official journal of the American Society of Transplantation and the, American Society of Transplant Surgeons, doi:10.1111/ajt.15849
Ray, Arbogast, Azithromycin and the Risk of Cardiovascular Death, The New England Journal of Medicine, doi:10.1056/NEJMoa1003833
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Rossi, Nguyen, Zimmermann, Boucenna, Dubret et al., Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study, doi:10.3390/ph13100317
Trinkley, Page, Yamanouye, Tisdale, QT interval prolongation and the risk of torsades de pointes: essentials for clinicians, Current Medical Research and Opinion, doi:10.1185/03007995.2013.840568
Vandenberk, Vandael, Robyns, Vandenberghe, Garweg et al., Which QT Correction Formulae to Use for QT Monitoring?, JAHA, doi:10.1161/JAHA.116.003264
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Yang, Yu, Xu, Shu, Ja et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600%2820%2930079-5
Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clinical Infectious Diseases, doi:10.1093/cid/ciaa237
Yazdany, Kim, Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know, Ann Intern Med, doi:10.7326/M20-1334
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet, doi:10.1016/S0140-6736%2820%2930566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit